KYAN Technologies: Difference between revisions

Line 17:

==Traction==

KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web |last=admin |date=2023-05-29 |title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients |url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. Their facility is located in [[Temasek Life ~~Science~~ Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.

KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web |last=admin |date=2023-05-29 |title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients |url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. Their facility is located in [[Temasek Life Sciences Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.

In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform<ref>{{Cite web |last=admin |date=2025-02-05 |title=KYAN Technologies announces collaboration with OncoCare Malaysia |url=https://kyantechnologies.com/kyan-technologies-announces-collaboration-with-oncocare-malaysia/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>.

@@ Line 17: / Line 17: @@
 ==Traction==
-KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web |last=admin |date=2023-05-29 |title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients |url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. Their facility is located in [[Temasek Life Science Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.
+KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web |last=admin |date=2023-05-29 |title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients |url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. Their facility is located in [[Temasek Life Sciences Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets.
 In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform<ref>{{Cite web |last=admin |date=2025-02-05 |title=KYAN Technologies announces collaboration with OncoCare Malaysia |url=https://kyantechnologies.com/kyan-technologies-announces-collaboration-with-oncocare-malaysia/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>.